ERS

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

Retrieved on: 
Wednesday, September 6, 2023
COPD, European Respiratory Society, International, ERS, Chronic obstructive pulmonary disease, Experimental Lung Research, VRNA, MD, Risk, European Respiratory Journal, Pharmaceutical industry

LONDON and RALEIGH, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces an oral presentation on an additional analysis from its successful Phase 3 ENHANCE-1 study with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at the European Respiratory Society (“ERS”) International Congress 2023.

Key Points: 
  • LONDON and RALEIGH, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces an oral presentation on an additional analysis from its successful Phase 3 ENHANCE-1 study with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at the European Respiratory Society (“ERS”) International Congress 2023.
  • The abstract is available to conference attendees on the ERS website and will be published in an upcoming issue of the peer reviewed publication, European Respiratory Journal.
  • The presentation will highlight additional analyses of the ENHANCE-1 24-week exacerbation data which demonstrated treatment with ensifentrine resulted in a substantial decrease in the rate and risk of moderate COPD exacerbations as well as moderate and severe COPD exacerbations.
  • Furthermore, it will highlight the impact of ensifentrine treatment on healthcare resource utilization related to COPD including fewer physician’s office visits, emergency department visits and hospitalizations compared with placebo treatment.

ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement

Retrieved on: 
Tuesday, September 5, 2023
Nobel Prize, CRISPR, Therapy, Genomics, Biotechnology, Gene editing, Cas9, Research, ERS, Collection, Health, NICE, Homologous recombination, Pharmaceutical industry

DUBLIN and NICE, France, Sept. 5, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with AlgenScribe SAS ('AlgenScribe'). This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio. 

Key Points: 
  • DUBLIN and NICE, France, Sept. 5, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with AlgenScribe SAS ('AlgenScribe').
  • This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio.
  • ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9.
  • The ERS patent portfolio is the definitive collection of proprietary rights to this gene editing technology.

ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement

Retrieved on: 
Tuesday, September 5, 2023
Nobel Prize, CRISPR, Therapy, Genomics, Biotechnology, Gene editing, Cas9, Research, ERS, Collection, Health, NICE, Homologous recombination, Pharmaceutical industry

DUBLIN and NICE, France, Sept. 5, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with AlgenScribe SAS ('AlgenScribe'). This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio. 

Key Points: 
  • DUBLIN and NICE, France, Sept. 5, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with AlgenScribe SAS ('AlgenScribe').
  • This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio.
  • ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9.
  • The ERS patent portfolio is the definitive collection of proprietary rights to this gene editing technology.

Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences

Retrieved on: 
Friday, September 1, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, ERS, Arrowhead, RNA interference, International Congress on Medieval Studies, Conference, European Respiratory Society, Pharmaceutical industry, Rare-earth element

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
    Citi’s 18th Annual BioPharma Conference – September 6, 2023
    European Respiratory Society (ERS) International Congress – September 9-13, 2023
    Title: A First-in-human Study of ARO-RAGE, an RNAi Therapy Designed to Silence Pulmonary RAGE Expression
    Baird 2023 Global Healthcare Conference – September 12, 2023
    Morgan Stanley 21st Annual Global Healthcare Conference – September 13, 2023
    2023 Cantor Fitzgerald Global Healthcare Conference – September 27, 2023
    Webcast links and presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

Retrieved on: 
Monday, August 28, 2023
Safety, ERS, European Respiratory Society, Fibrosis, Congress, International, Therapy, International Congress on Tuberculosis, SAN, Pharmaceutical industry, Risk management

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced three upcoming presentations at the European Respiratory Society (ERS) International Congress 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced three upcoming presentations at the European Respiratory Society (ERS) International Congress 2023.
  • The congress will take place in Milan, Italy from September 9, 2023 to September 13, 2023.
  • Title: Safety, tolerability and antifibrotic activity if bexotegrast: Phase 2a INTEGRIS-IPF Study (NCT04396756)

DOMO TACTICAL COMMUNICATIONS RECEIVES THE BRONZE AWARD FROM THE DEFENCE EMPLOYER RECOGITION SCHEME (ERS)

Retrieved on: 
Thursday, August 17, 2023
DTC, Organic, Private sector, Secretary of Defense Employer Support Freedom Award, Armed Forces Covenant, Covenant, Military, Bronze Award, Government, ERS, Public sector, United States Senate Committee on Armed Services, NHS, Security (finance)

Hampshire, United Kingdom, Aug. 17, 2023 (GLOBE NEWSWIRE) -- CODAN/DTC (Domo Tactical Communications) is proud to announce that it has received the Bronze Award from the Defense Employer Recognition Scheme (ERS) after signing The Armed Forces Covenant, a promise to those who serve or who have served, and their families.

Key Points: 
  • Hampshire, United Kingdom, Aug. 17, 2023 (GLOBE NEWSWIRE) -- CODAN/DTC (Domo Tactical Communications) is proud to announce that it has received the Bronze Award from the Defense Employer Recognition Scheme (ERS) after signing The Armed Forces Covenant, a promise to those who serve or who have served, and their families.
  • The Defence Employer Recognition Scheme (ERS) encourages employers to support defence and inspire others to do the same.
  • The Covenant brings together the government, businesses, local authorities, charities, and the public in order to support those who serve.
  • DTC is very proud to be a member of the Armed Forces Covenant and support members of the Armed Services and their families.

Honda to Participate in FIA Formula One World Championship from 2026 Season as Power Unit Supplier for Aston Martin Aramco Cognizant Formula One Team

Retrieved on: 
Wednesday, May 24, 2023
Aston, Mexican Grand Prix, Partnership, Formula One Group, FIA, Marketing, HRC, Scuderia AlphaTauri, Season, FOA, Research, Carbon, Attitude, ERS, Saudi Aramco, Aston Martin in Formula One, 1965 Mexican Grand Prix, FOM, Dream, Honda Racing Corporation, Formula One, McLaren, Environment, Automotive industry, Electric motor, F1

TOKYO, May 24, 2023 - (JCN Newswire) - Honda Motor Co., Ltd. today announced plans to participate in the FIA(1) Formula One World Championship (F1) from the 2026 season as a power unit supplier.

Key Points: 
  • TOKYO, May 24, 2023 - (JCN Newswire) - Honda Motor Co., Ltd. today announced plans to participate in the FIA(1) Formula One World Championship (F1) from the 2026 season as a power unit supplier.
  • Honda has agreed to enter into a works partnership with the Aston Martin Aramco Cognizant Formula One Team to supply power units compliant with the new F1 power unit regulations which will take effect in the 2026 season.
  • These changes in F1 power unit regulations are consistent with the direction Honda has been taking toward the realization of carbon neutrality.
  • "I would like to welcome Honda and HRC to the Aston Martin Aramco Cognizant Formula One Team.

Everest Group Announces Winners of 2023 Engineering Services PEAK Matrix Provider of the Year Awards

Retrieved on: 
Thursday, August 10, 2023
Monochorionic twins, Ernst & Young Entrepreneur of the Year Award, National Engineering Services Pakistan, Internet of things, Life, IP, ERS, Global 2000, TCS, Internet, Investment, Machine learning, Sustenance, Digital, AI, HCLTech, D, Engineering, The Things

DALLAS, Aug. 10, 2023 /PRNewswire-PRWeb/ -- Everest Group today released the second annual edition of its Engineering Services PEAK Matrix Provider of the Year™ Awards. These awards recognize the engineering services providers that have consistently ranked as top performers across Everest Group's PEAK Matrix® assessments in the preceding year.

Key Points: 
  • "The Engineering Services PEAK Matrix Provider of the Year™ Awards recognize an elite group of engineering services providers who set themselves apart by exhibiting consistent leadership and top performance across many different categories," said Akshat Vaid, partner at Everest Group.
  • "Digital engineering is transforming businesses and helping efforts to create a sustainable world," said Vijay Anand Guntur, president, Engineering and R&D Services (ERS), at HCLTech.
  • 1 player in Everest Group's 2023 PEAK Matrix Provider of the Year award.
  • This achievement is a testament to HCLTech's record of being a preferred engineering services partner of Global 2000 companies in building innovative products and platforms."

ERS Genomics & Santa Cruz Biotechnology Enter Into CRISPR/Cas9 Licensing Agreement

Retrieved on: 
Thursday, August 10, 2023
Nobel Prize, CRISPR, Genomics, Gene editing, Biomedical Research, Cas9, Research, ERS, Collection, Gene, Pharmaceutical industry, Fine chemical, DALLAS

DUBLIN and DALLAS, Aug. 10, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Santa Cruz Biotechnology Inc ('SCBT,'). This is a non-exclusive licensing agreement granting SCBT access to the ERS CRISPR/Cas9 patent portfolio. 

Key Points: 
  • DUBLIN and DALLAS, Aug. 10, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Santa Cruz Biotechnology Inc ('SCBT,').
  • This is a non-exclusive licensing agreement granting SCBT access to the ERS CRISPR/Cas9 patent portfolio.
  • Santa Cruz Biotechnology offers Knock-Out, Activator and Nickase CRISPR products to most human and mouse protein encoding genes.
  • Eric Rhodes, CEO, ERS Genomics was equally positive about the new relationship: 'Santa Cruz has an established and impressive reputation for making innovative solutions accessible to scientists.

ERS Genomics & Santa Cruz Biotechnology Enter Into CRISPR/Cas9 Licensing Agreement

Retrieved on: 
Thursday, August 10, 2023
Nobel Prize, CRISPR, Genomics, Gene editing, Biomedical Research, Cas9, Research, ERS, Collection, Gene, Pharmaceutical industry, Fine chemical, DALLAS

DUBLIN and DALLAS, Aug. 10, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Santa Cruz Biotechnology Inc ('SCBT,'). This is a non-exclusive licensing agreement granting SCBT access to the ERS CRISPR/Cas9 patent portfolio. 

Key Points: 
  • DUBLIN and DALLAS, Aug. 10, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Santa Cruz Biotechnology Inc ('SCBT,').
  • This is a non-exclusive licensing agreement granting SCBT access to the ERS CRISPR/Cas9 patent portfolio.
  • Santa Cruz Biotechnology offers Knock-Out, Activator and Nickase CRISPR products to most human and mouse protein encoding genes.
  • Eric Rhodes, CEO, ERS Genomics was equally positive about the new relationship: 'Santa Cruz has an established and impressive reputation for making innovative solutions accessible to scientists.